Researchers led by Ursula Quitterer at ETH Zurich reported a new small-molecule compound—“Compound 10”—that shows promise in slowing Alzheimer’s disease progression. The work targets a novel mechanism implicated in Alzheimer’s pathology and was described as a fresh lead for disease-modifying strategy. The report characterizes “Compound 10” as a mechanistically differentiated chemical that builds on evolving understanding of disease biology beyond symptomatic approaches. Additional details on stage, efficacy magnitude, and translational path were not included in the article text provided. Still, the identification of a new target-and-compound combination from an academic team signals continued activity in the search for mechanistic therapies in Alzheimer’s. Follow-up data—such as preclinical efficacy, biomarkers, and safety—will determine whether the compound advances toward more formal development steps.